Lupin Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Solid quarter, margin-led beat: Revenue grew 13% YoY while gross margins surged to 67.8% from 59.6% last year, driven by a favorable product mix shift away from low-margin in-licensed products and operational efficiencies.
• Spiriva is delivering, but the bar is moving: The Tiotropium launch captured a 30% market share in 10 months and contributed 4–5 percentage points to gross margins, though management deflected on whether the prior 40% share target still stands.
• The pipeline is pivoting to complexity: Over 70% of FY25 U.S. launches will be non-oral solids, and complex products are expected to grow from ~40% to 50–60% of the U.S. portfolio, a mix shift that structurally supports higher margins.
• Guidance underwhelms relative to the setup: FY25 revenue growth guided to "close to 10%" and EBITDA margin to "20% plus," with Mirabegron upside explicitly excluded, leaving room for positive surprise if litigation resolves favorably.
• What to watch next quarter: The Mirabegron relaunch timing and competitive dynamics, whether the brand's June coupon change disrupts Spiriva's pricing stability, and the pace of India prescription growth as the market recovers from a sluggish 5.7% quarter.

U.S. Business: The Margin Engine

• Revenue base holding above \$200 mn: Q4 U.S. sales were \$209 mn, marginally lower QoQ on constant currency as seasonal product volume declines and additional Darunavir competition offset base business strength and new product contributions from Tiotropium and generic Prolensa.
• Pricing erosion remains benign: Single-digit price erosion over the last 12 months, with drug shortages creating a structural stabilization dynamic as economically non-viable products exit the market and regulators take notice.
• Spiriva share stable at 30%: Order book and share show no tapering; pricing has been very stable with minimal discounting needed for substitution, though the brand's June coupon change introducing a \$35 out-of-pocket cap may require a strategy adjustment.
• Mirabegron is the near-term swing factor: A temporary restraining order is in place with no preliminary injunction; management feels "pretty strongly" about its non-infringement and invalidity position and expects to relaunch "shortly," but the competitive window is narrowing with 2–3 players expected in the next 12 months.
• Path to \$1 bn and beyond: With the current pipeline of PIV products, injectables, and complex generics, FY26 revenue should approach \$1 bn; exclusive launches like Tolvaptan and peptide injectables could push quarterly U.S. sales closer to \$250 mn in FY26.

Vinita Gupta: "I think that Astellas has really filed multiple patent after patent, and to prevent affordable generics to come to market. But we feel pretty strongly about our position, both from a non-infringement as well as invalidity standpoint."

Margin Trajectory & Operational Delivery

• Gross margin leap is structural, not one-off: Q4 gross margins of 67.8% benefited from a reduced share of in-licensed products (down to ~11% from 15–16%), increased volumes, and higher inventory carried for geopolitical risk mitigation, but the underlying drivers of complex product mix and process efficiency gains are durable.
• Process efficiency delivered INR 800–900 crores cumulatively: Route-to-synthesis improvements, AVD programs, and vendor initiatives contributed ~INR 400 crores over 3–4 years, while operational fixes addressing supply failures, air freighting, inventory write-offs, workforce rationalization, and footprint reduction added another INR 400–500 crores, though partly eroded by price erosion.
• EBITDA margin guided conservatively: Q4 EBITDA margin improved ~30 bps QoQ to 20.4% despite higher R&D and seasonal effects; FY25 guidance is "20% plus," with Mirabegron explicitly excluded and representing potential upside.
• Medium-term ambition of 23–24%: Management sees a path to peer-level margins in the next 2–3 years, driven by operating leverage as complex products scale and cost discipline holds, though R&D spend will increase slightly in FY25.

Ramesh Swaminathan: "If one, all of this is actually done, surely you would be, to be something to be around the 23-24% points in line with our peers, so to speak."

India & Emerging Markets: The Growth Anchor

• India prescription business outpacing a sluggish market: Q4 India revenue grew 8.3% YoY (9.6% for FY24), with the prescription business growing 8.7% and 9.3% ex-Cidmus, roughly 1.2x the IPM growth rate; core therapies like cardio and respiratory grew well ahead of market.
• Trade generics carved out for focus: The trade generics business has been moved into a 100% wholly-owned subsidiary to enhance agility and capture growth from organized retail, hospital, and institutional segments, including Tier 2/3 towns.
• Confident of sustained outperformance: Management targets 25–30% above IPM growth in FY25 and has already started seeing this trajectory in April, with plans to launch ~20 products during the year.
• Emerging markets are a mixed bag with bright spots: Philippines is highly profitable with stable high growth; South Africa has turned around in recent quarters; Mexico is resurging after a 10-month facility closure; Brazil remains a low-margin challenge. Forex risk can eat into gains.
• Diagnostics is scaling but burning: Revenue grew 160% YoY with ~40 labs operating, but the burn increased in FY24 and will stay at similar levels in FY25 before improving; management expects the business to grow to a multiple of the current INR 60+ crores in five years but calls it "certainly not the focus area."

Pipeline & Portfolio Evolution

• Complex products are the strategy, not a tactic: Complex products currently represent ~40% of the U.S. portfolio and are expected to reach 50–60% in the next few years; over 70% of FY25 launches will be non-oral solids, and ~50% of R&D investment is concentrated in inhalation and complex injectables.
• Respiratory franchise building beyond Spiriva: Fostair holds a dominant share in most European countries and is a material growth driver; the Ellipta platform and two key products are progressing with material progress expected by end-FY25; Respimat should file at end-FY25, dependent on externally manufactured device supply.
• Injectable capacity coming online: The Nagpur Unit 2 injectable block, last inspected 12 months ago, currently sells only 1–2 products but is expected to generate 5–6 filings and 5–6 launches on a steady state over the next 2–3 years.
• Biosimilars are a cautious long-term bet: Enbrel revenue grew over the past year with launches in Russia, Canada (via Sandoz), and planned entries in the Middle East and Australia; the broader biosimilar portfolio is being built cautiously as a differentiating platform, with capabilities also leveraged for India oncology and immunology products.
• Peptide injectables represent the next wave: Ganirelix was the first peptide launch; Liraglutide (Victoza/Saxenda) has been filed and approval is expected soon, with launch timing dependent on patent settlements; the market could be competitive but approval timeline dispersion may make it attractive.
• Lower ANDA filings reflect deliberate focus, not slowdown: Only 6 ANDAs were filed in FY24 as the company pivots to fewer but more impactful complex product filings; FY24 was also a "repurposed year" with some filings slipping into Q1 FY25.

Vinita Gupta: "I wouldn't say that it's a material share opportunity unless folks get out of the market. So it's really going to be more of a learning opportunity for us."

Capital Allocation & Balance Sheet

• Net debt nearly eliminated: Reduced from INR 2,527 crores in March 2023 to INR 477 crores, reflecting strong cash generation and disciplined capital allocation.
• Impairment charge cleans up the portfolio: INR 201 crores in impairment related to discontinued ANDAs (mostly bought-out assets in the U.S.) and certain tangible assets not being put to use, including three products from the Anglo-French acquisition in India discontinued due to regulatory rulings.
• Bolt-on M&A to fill capability gaps: The Medisol transaction, a French complex injectable company, closed during the quarter, expanding the complex generics position in Europe; two accretive established brands were acquired from Sanofi for Europe and Canada to complement the respiratory portfolio.
• Working capital temporarily elevated: Net working capital increased to 105 days from 96 days QoQ, primarily due to higher inventory carried as geopolitical risk mitigation for Middle East exposure.

Guidance & Commitments

Key Metrics